Failure of intravenously administered immunoglobulin in the treatment of neonatal myasthenia gravis

Neonatal myasthenia gravis is uncommon and life threatening. We describe the use of intravenously administered immunoglobulin, in addition to conventional modalities, in a neonate with severe neonatal myasthenia gravis. However, despite this aggressive management, the child had a prolonged period of...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pediatrics 1999-02, Vol.134 (2), p.233-235
Main Authors: Tagher, Robert J., Baumann, Robert, Desai, Nirmala
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Blood Transfusion
Cholinesterase Inhibitors - therapeutic use
Diseases of striated muscles. Neuromuscular diseases
Female
Humans
Immunoglobulins, Intravenous - therapeutic use
Infant, Newborn
Medical sciences
Myasthenia Gravis - therapy
Neostigmine - therapeutic use
Neurology
Pregnancy
Pregnancy Complications - physiopathology
Pregnancy Complications - therapy
Treatment Failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neonatal myasthenia gravis is uncommon and life threatening. We describe the use of intravenously administered immunoglobulin, in addition to conventional modalities, in a neonate with severe neonatal myasthenia gravis. However, despite this aggressive management, the child had a prolonged period of weakness requiring intensive care. (J Pediatr 1999;134:233-5)
ISSN:0022-3476
1097-6833
DOI:10.1016/S0022-3476(99)70422-1